Evidence map›Paper›PMID 38319561›Full record

ArticleAnalytical sciences : the international journal of the Japan Society for Analytical Chemistry2024

Improvement of limit of detection in primer extension-based multiplexed mutation assay using capillary electrophoresis.

Takahiro Ando, Takahide Yokoi, Chihiro Manri, Takashi Anazawa, Takeshi Ishida

Open access · hybridAbstract read
In one paragraph

Article in Analytical sciences : the international journal of the Japan Society for Analytical Chemistry, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Takahiro AndoResearch & Development Group, Hitachi, Ltd., 1-280 Higashi-Koigakubo, Kokubunji-shi, Tokyo, 185-8601, Japan. takahiro.ando.dc@hitachi.com.ORCID http://orcid.org/0000-0001-8239-5437
Takahide YokoiResearch & Development Group, Hitachi, Ltd., 1-280 Higashi-Koigakubo, Kokubunji-shi, Tokyo, 185-8601, Japan.
Chihiro ManriResearch & Development Group, Hitachi, Ltd., 1-280 Higashi-Koigakubo, Kokubunji-shi, Tokyo, 185-8601, Japan.
Takashi AnazawaResearch & Development Group, Hitachi, Ltd., 1-280 Higashi-Koigakubo, Kokubunji-shi, Tokyo, 185-8601, Japan.
Takeshi IshidaResearch & Development Group, Hitachi, Ltd., 1-280 Higashi-Koigakubo, Kokubunji-shi, Tokyo, 185-8601, Japan.
Hitachi (Japan) · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

One of the challenges in liquid biopsy for early cancer detection is ascribed to the fact that mutation DNA often represents an extremely small ratio of less than 1% compared to wild-type genes in blood. However, in conventional fragment analysis with capillary electrophoresis (CE), the detectable allele frequency could be about 5%. In this work, we developed an original reagent-based fragment analysis with single base extension (SBE) reactions for cancer-associated mutation assay using a commercially available CE device, and investigated on a possibility of improvement of limit of detection (LOD) for genetic mutation. First, after adjustment of reagent conditions for the SBE reactions, the linear relationship between gene template concentration and fluorescence intensity was obtained from 1 to 100 fmol of target genes. Next, from the results of an experiment to detect mutation EGFR L858R at abundance ratios of mutant type to wild type (100-fmol template) of 0, 1, 5, and 10%, it was shown that the target gene can be detected with LOD of 0.33%. This high sensitivity was realized in part by separating fluorescently labeled substrates into an individual tube for an each-colored SBE reaction. Moreover, mutations EGFR L858R and KRAS G12V were simultaneously detected at sensitivities equivalent to LODs of 0.57 and 0.47%, respectively. These results indicate that < 1% of mutations in multiplex gene mutations can be simultaneously detected, and that possibility suggests that the developed method can be used in clinical practice for detecting cancers.

Indexed as

Electrophoresis, CapillaryNeoplasmsErbB ReceptorsHumansLimit of DetectionMutationErbB ReceptorsCancer diagnosisCapillary electrophoresisGene mutation detectionSingle nucleotide extension

Identifiers

PMID38319561
PMCPMC10961290
OpenAlexW4391577001

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.